Condition: Acute Ischemic Stroke · Sponsor: Capital Medical University
This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.
This description comes directly from the study's public registry record.
Xunming Ji, MD/PhD · 01083198962 · jixm@ccmu.edu.cn
Chuanjie Wu, MD · 01083199439 · wuchuanjie@ccmu.edu.cn
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital, Capital Medical University | Beijing, None Selected, China | Not Yet Recruiting |
| Anji County People's Hospital | Huzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07513233